… Therefore, we herein attempted to modify the structures of commercially available amilorides
and investigated the structure–activity relationship (SAR) of these synthetic derivatives to …

… Design, synthesis, and structure– activity relationships of novel 2-substituted pyrazinoylguanidine
epithelial sodium … -02, a novel epithelial sodium channel blocker with potential clinical …

… on asthma, cystic fibrosis (CF), and chronic obstructive pulmonary disease (COPD), three …
anion channel [53]. The lack of functional CFTR and subsequent epithelial sodium channel (…

… Amiloride exerts its clinical effects through inhibition of renal epithelial sodium channels (ENaC),
[18… Structure–activity relationships (SAR) of amiloride analogs against NHE1 have been …

… channels including the epithelial sodium channel (ENaC) and the outwardly rectifying chloride
channel … for new therapies as drugs that will only improve epithelial chloride transport, but …

… obstruction and increased epithelial sodium channel (ENaC) … mice with cystic fibrosis-like
lung disease [11, 62] led to novel … of chronic bronchitis and emphysema in beta-epithelial Na+ …

… Design, synthesis, and structureactivity relationships of novel 2-substituted pyrazinoylguanidine
epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J …

… by increased absorption via ENaC epithelial sodium channel. The dehydration of the liquid
… SPX-101 is a novel epithelial sodium channel-targeted therapeutic for cystic fibrosis that …

… of epithelial sodium channel (ENaC) blockers that have been studied as experimental therapeutic
agents for cystic fibrosis (… in asthma and in chronic obstructive pulmonary disease. The …

… Design, synthesis, and structureactivity relationships of novel 2-substituted pyrazinoylguanidine
epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J …